MTOR and cancer: Nevertheless, our findings suggest that HH-driven paediatric cancers can be targeted by inhibition of the PI3K/mTOR pathway and raise the interesting possibility that this strategy might be exceptionally efficient in cancers that are highly dependent on non-canonical HH signalling and that are resistant to SMO inhibitors.